Medical University of Vienna
Vienna, 1090, Austria
NCT Number: NCT01768507
Heme oxygenase 1 (HO-1) serves as a protective gene. The aim of this clinical trial is to evaluate the HO-1 stimulation of resveratrol in healthy humans.
Looking for future studies?
Notify Me18 year–45 year
Male
Interventional
Not applicable
Vienna, 1090, Austria
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
5 g (10 capsules) as single oral dose on day 1
Time frame: 1 month
Daniel Doberer
Other
The Effects of the Dietary Supplement Trans-resveratrol on Heme Oxygenase-1 (HO-1) and Sirtuins Expression in PBMCs in Healthy Male Subjects: A Pilot Study.
Acronym: REVAHS
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00682370
Genetic Polymorphism, Healthy Subjects
Vienna, Austria
View Trial DetailsNCT06570655
Healthy Subjects
Hangzhou, China/Zhejiang, China
View Trial DetailsNCT03869372
Colonic Diseases, Colonic Diseases, Functional
Pittsburgh, Pennsylvania, United States
View Trial DetailsNCT00001258
Basal Ganglia Diseases, Brain Diseases
Bethesda, Maryland, United States
View Trial Details